Compare · HSKA vs LMDX
HSKA vs LMDX
Side-by-side comparison of Heska Corporation (HSKA) and LumiraDx Limited (LMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HSKA and LMDX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- LMDX is the larger of the two at $2.23B, about 1.6x HSKA ($1.41B).
- HSKA has more recent analyst coverage (7 ratings vs 4 for LMDX).
- Company
- Heska Corporation
- LumiraDx Limited
- Price
- $120.00+0.05%
- $0.02-53.80%
- Market cap
- $1.41B
- $2.23B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1997
- News (4w)
- 0
- 0
- Recent ratings
- 7
- 4
Heska Corporation
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC and Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus +TM veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; HeskaView, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. Additionally, the company provides a line of bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. It sells its products to veterinarians through a field organization, a telephone sales force, and third party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is based in Loveland, Colorado.
Latest HSKA
- Bee Vaccine Pioneer Dalan Secures $4.5M to Fuel Global Expansion and Product Development
- SEC Form 15-12G filed by Heska Corporation
- SEC Form 4 filed by Maples Sharon J.
- SEC Form 4 filed by Eyl Steven M.
- SEC Form 4 filed by Hasenmaier Joachim A.
- SEC Form 4 filed by Davis Stephen L
- SEC Form 4 filed by Antin Robert L
- SEC Form 4 filed by Sveen David E.
- SEC Form 4 filed by Humphrey Scott
- SEC Form 4 filed by Furlong Mark F
Latest LMDX
- SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)
- SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)
- SEC Form 6-K filed by LumiraDx Limited
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Dow Surges Over 100 Points; Commercial Metals Posts Upbeat Q1 Results
- Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- LumiraDx shares are trading lower after the company announced its securities will be suspended from trading on Nasdaq at the open of business tomorrow.
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Crude Oil Falls Sharply; Ambrx Biopharma Shares Spike Higher
- US Stocks Mixed; Nasdaq Jumps Over 100 Points